3,530
Views
6
CrossRef citations to date
0
Altmetric
Reviews

Application of radiation omics in the development of adverse outcome pathway networks: an example of radiation-induced cardiovascular disease

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, , ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 1722-1751 | Received 10 May 2022, Accepted 28 Jul 2022, Published online: 24 Aug 2022

Figures & data

Table 1. List of the transcriptomic studies on radiation-induced CVD.

Table 2. List of the miRNA analyses of radiation-induced CVD.

Table 3. List of the proteomics studies on radiation-induced CVD.

Table 4. List of the metabolomics studies on radiation-induced CVD.

Table 5. List of the biofluid analyses on radiation-induced CVD.

Figure 1. Categories of radiation omics studies to support proposed CVD AOP. Available types of omics data are represented across key events in the CVD AOP network as colored boxes (modified from Chauhan, Hamada, et al. (Citation2021)).

Figure 1. Categories of radiation omics studies to support proposed CVD AOP. Available types of omics data are represented across key events in the CVD AOP network as colored boxes (modified from Chauhan, Hamada, et al. (Citation2021)).

Figure 2. The application of omics data in the development of AOP for radiation-induced CVD. The different levels of omics data obtained from the cell, animal, and human samples can enrich the AOP framework alongside available knowledge from non-omics data, epidemiological findings, and mechanistic, and mathematical modeling. Together, this information can be integrated across biological levels of organization and provide confident bioindicators for the development of bioscreening tools that can support radiation risk assessment. MIE: molecular initiating events; KE: key events; AO: adverse outcome. The figure is created with BioRender.com.

Figure 2. The application of omics data in the development of AOP for radiation-induced CVD. The different levels of omics data obtained from the cell, animal, and human samples can enrich the AOP framework alongside available knowledge from non-omics data, epidemiological findings, and mechanistic, and mathematical modeling. Together, this information can be integrated across biological levels of organization and provide confident bioindicators for the development of bioscreening tools that can support radiation risk assessment. MIE: molecular initiating events; KE: key events; AO: adverse outcome. The figure is created with BioRender.com.
Supplemental material

Supplementary_Table_1.xlsx

Download MS Excel (11.8 KB)